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Background: Renal artery stenosis (RAS) is associated with high cardiovascular mortality and significant clinical
complications, including resistant hypertension and ischemic nephropathy. Despite availability of endovascular revascu-
larization techniques, determining which patients should undergo revascularization and the timing of the procedure still
are controversial. Several studies have reported a higher frequency of the DD genotype of the insertion/deletion (I/D)
polymorphism of the angiotensin converting enzyme (ACE) gene in patients with RAS, and one study found higher
mortality in patients with the DD genotype.
Material and methods: We retrospectively studied 100 patients with documented atherosclerotic RAS and evaluated
long-term (median follow-up, 28 months) mortality, blood pressure control, and renal function in relation to the ACE
genotype and two therapeutic strategies, that is, endovascular treatment with percutaneous renal transluminal angio-
plasty or stenting (ET group) versus conservative drug therapy (CT group).
Results: Comparison between therapeutic groups showed a higher cumulative probability of survival (86.7% vs 67.1%),
better blood pressure control (57.4% vs 29%), and slower decline in renal function (17.9% vs 48.4%) in the ET group. The
DD genotype was strongly represented in our study patients (DD, 50%; II, 15.5%; I/D, 34.5%), but bore no relation to
mortality, blood pressure control, decline in renal function, or rate of recurrent stenosis.
Conclusions: Conservative medical treatment of RAS, compared with endovascular treatment, is associated with higher
mortality, poorer blood pressure control, and impaired renal function over the long term. Early endovascular treatment
enables amelioration of this unfavorable evolution. The DD genotype does not predict clinical outcome of RAS. (J Vasc
Surg 2004;39:140-7.)
In selected populations renal artery stenosis (RAS) is a
relatively common hypertensive disorder characterized by
significant clinical complications such as resistant hyperten-
sion, recurrent pulmonary edema, and ischemic nephropa-
thy, which in turn give rise to high cardiovascular mortali-
ty.1-3 Five years after diagnosis, progression of luminal
narrowing occurs in 51% of patients and renal artery occlu-
sion occurs in 5% of patients; renal atrophy develops in 20%
of patients after 2 years.4-5 The mortality rate in patients
with bilateral RAS is 38% after 2 years3; in patients with
end-stage renal disease due to RAS, it is 80% after 5 years6,
and in patients with RAS and coronary artery disease it is
67% after 4 years.7
Surgical treatment of RAS has been used extensively,
with satisfactory results but with relatively high periopera-
tive mortality and morbidity. Percutaneous transluminal
renal angioplasty (PTRA) alone or in combination with
stent implantation (PTRA-S) is a valid alternative to sur-
gery.
Despite availability of these less invasive techniques and
the severe prognosis with RAS, determination of which
patients should undergo revascularization and the timing of
the procedure are still matters of controversy. In noncon-
trolled trials, improved blood pressure and control and
stabilization of renal function were observed after restora-
tion of luminal patency.8-11 Nevertheless, the only three
randomized controlled trials comparing PTRA and conser-
vative medical therapy showed no significant differences in
outcome and a number of PTRA-related complica-
tions,12-14 which suggests caution in extensive PTRA treat-
ment.
Genetic predisposition may contribute to the patho-
genesis of RAS, and identification of the gene variants
involved in the pathogenesis may improve prognosis and
therapy. In recent years, attention has been focused on the
possible association with insertion/deletion (I/D) poly-
morphism of the angiotensin converting enzyme (ACE)
gene. Several studies have reported a higher frequency of
DD homozygosity in patients with RAS (on average, DD
genotype, 49%; range, 41%-54.5%) than is usually reported
for the general population (on average, 30%-32%).15-17 In
addition, Losito et al18 reported a higher mortality rate in
patients with this genotype compared with patients with
other genotypes (6-year survival, 45.4% vs 73.4%). Inas-
much as ACE I/D polymorphism is a major determinant of
circulating ACE, with higher serum levels in subjects ho-
mozygous for the D allele,19 activation of the renin-angio-
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tensin system and production of angiotensin II may be
exaggerated in DD carriers.
The purpose of the present study was to evaluate pos-
sible interactions between ACE I/D polymorphism, type
of treatment, and complications, including mortality, asso-
ciated with RAS.
MATERIAL AND METHODS
Patients. Records for all patients with angiographi-
cally significant RAS (50%) identified from May 1996 to
May 2002 at our institution were retrospectively examined
for the study. One hundred twenty-two patients were ini-
tially recruited. Most of the patients underwent angio-
graphic evaluation, because of high or moderate index of
clinical suspicion for renovascular hypertension according
to Mann and Pickering criteria20 or because of suggestive
findings at Doppler ultrasound scanning. These patients
generally had severe hypertension, requiring two or more
drugs, in association with clinically evident atherosclerosis
in other regions, mainly the coronary arteries and lower
extremities, or some degree of renal impairment. A second
group of patients with hypertension was enrolled because
of significant RAS recognized at angiographic evaluation
performed for other causes, mainly lower extremity vascular
disease.
At baseline angiography, 226 renal arteries were stud-
ied, and 127 significant stenoses were detected.
Patients with nonatherosclerotic RAS (8 patients with
fibrodysplasia, 2 patients with vasculitis) and patients with
insufficient follow-up data (12 patients did not have at least
one follow-up examination) were excluded. Records for
100 patients were finally considered suitable for statistical
analysis.
The study was approved by our institutional review
board, and all patients gave informed consent.
Treatment. Two groups of patients were observed.
Thirty-seven patients received conservative therapy (CT
group). In these patients, the diagnosis was first made at
angiographic evaluation performed because of other
causes, usually lower extremity arteriopathy, in the Vascular
Surgical Department at our hospital. As the primary thera-
peutic goal was not renovascular disease, but arterial insuf-
ficiency of the legs, the possibility of renal endovascular
therapy was not considered for most patients in this group.
In a number of patients in this group, the possibility of
PTRA or PTRA-S was excluded because of cardiac condi-
tions, such as symptomatic coronary artery disease (CAD).
Sixty-three patients received endovascular therapy (ET
group). This group of patients was first evaluated because
of resistant hypertension or unexplained azotemia, and the
diagnosis was made in our Hypertension Unit. Of the
patients with RAS considered as a whole, 48% had CAD,
and 78% and 59%, respectively, had ultrasonic or angio-
graphic evidence of carotid or lower extremity artery dis-
ease. The relative percentages of areas of vascular disease in
the CT and ET groups are reported in Table I. CAD was
diagnosed on the basis of clinical findings (typical symp-
toms requiring specific therapy) or instrumental evidence
(resting or exercise-induced electrocardiographic alter-
ations, coronary angiography). Peripheral arterial disease
(carotid artery or lower extremities) was diagnosed on the
basis of ultrasonic or angiographic evidence of one or more
areas of stenosis resulting in at least 50% reduction in the
vessel lumen.
At baseline angiography, 29.5% of the CT group and
26.5% of the ET group had greater than 50% stenosis
bilaterally, and subocclusive lesions were detected in 36.1%
and 40.6% of patients, respectively, in the two groups. In
the population as a whole, stenosis was ostial in 52.6% of
cases and located in the proximal third of the vessel in the
remaining cases.
All of these patients were subsequently recalled and
examined at scheduled follow-up visits, and venous blood
samples for genetic analysis were collected after obtaining
informed consent. Patients in both groups received the
least number of hypotensive drugs to adequately control
blood pressure (target blood pressure 140/90 mm Hg).
The most frequently used classes of drugs were ACE inhib-
itors (62% of patients), diuretics (furosemide in 46.7%,
other diuretics in 15.2% of patients), calcium antagonists
(48.9% of patients), and -blockers (30.4% of patients).
There was no statistically significant difference in percent-
age of any single class of drugs between the two groups of
patients (data not shown).
Until 1999, renal artery interventions generally con-
sisted of PTRA, and stent implantation (Palmaz model) was
performed only in patients in whom PTRA results were
unsatisfactory. Since 1999, all patients have undergone
revascularization with primary PTRA-S (Corinthias model;
stent diameter, 4-7 mm). Of 63 patients who underwent
revascularization, PTRA was performed in 32.8%, and
PTRA-S in 67.2%.
Immediate complete success of a procedure was de-
fined when less than 50% residual artery stenosis was ob-
tained. All procedures were successful. After PTRA-S, pa-
tients received heparin intravenously for 24 hours, and
antiplatelet therapy was given indefinitely.
Procedural complications included partial renal infarc-
tion (superior pole) (n  2), cholesterinic embolism in the
lower extremities (n  1), non-Q myocardial infarction (n
 1), and acute worsening of preexisting renal insufficiency
(n  2). It should be noted that three of these complica-
tions occurred in the same patient.
Follow-up. Clinical, biochemical, and radiologic fol-
low-up data were available for a median period of 28
months (range, 1-60 months), and the findings were com-
pared with patient information collected at diagnosis (CT
group) or just before PTRA-S (ET group).
Outcome in terms of blood pressure response was
classified as follows. Hypertension was considered cured
when blood pressure was less than 140/90 mm Hg without
use of antihypertensive medication; improved when there
was either a decrease in diastolic or systolic blood pressure
of at least 10% with the same or fewer medications, or no
change in blood pressure with fewer drugs; and worsened
when there was either an increase in diastolic or systolic
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blood pressure of at least 10% with the same or more drugs,
or no change in blood pressure with more drugs. In all
other cases blood pressure was considered unchanged.21,22
Renal function was considered improved when a de-
crease in serum creatinine (Cr) concentration of at least 0.2
mg/dL (17.7 mol/L) was observed, worsened when
serum Cr concentration increased by at least 0.2 mg/dL,
and unchanged when variation was less than 0.2 mg/dL.22
Renal artery patency was checked at angiography or
echo Doppler ultrasound scanning in the ET group. Recur-
rent stenosis was angiographically defined as reduction in
lumen diameter of at least 50% in a previously revascular-
ized renal artery. When patency was checked with echo
Doppler scanning and recurrent stenosis was suspected,
renal angiography was systematically repeated for
confirmation.
Mutation analysis.
Genomic DNA was extracted from whole blood with
standard methods.
To determine ACE genotype, genomic DNA was am-
plified with polymerase chain reaction with the hace3
primer pair. Each sample with the DD genotype was sub-
jected to a second independent polymerase chain reaction
amplification with the hace5 primer pair, which recognized
only the I allele.16
Statistical analysis. Data analysis was performed with
SPSS version 10.0 for Windows (SPSS, Chicago, Ill).
Quantitative values were expressed as mean  SD. The
Student t test for unpaired observations was used for nor-
mally distributed variables, and the Mann-Whitney U test
for nonnormally distributed variables. Comparison of pro-
portions was carried out with cross-tabulation, Pearson 2
test, and Fisher exact test.
To define which baseline variables could serve as useful
predictors of subsequent clinical outcome, various multi-
variate regression models were used. For survival, analysis
was performed with the Cox proportional hazards regres-
sion model. A logistic regression model was used for the
other three main clinical outcomes: blood pressure control
(improved vs unchanged or worsened), renal function
(worsened vs unchanged or improved), and arterial recur-
rent stenosis (yes or no). Only variables achieving a level of





(n  37) P
Age (y) 65.9  8.5 69.5  8.5 .05*
Gender (M/F) 40/23 27/10 NS†
Smoker 34 (56.7) 27 (73) NS†
Systolic BP (mm Hg) 168.2  22.3 158.9  27.33 NS‡
Diastolic BP (mm Hg) 95.32  10.18 90.54  12.35 .05*
Total cholesterol (mg/dL) 217.7  47.56 211.52  49.88 NS*
LDL cholesterol 148.1  35.96 151.2  43.31 NS*
HDL cholesterol 45.63  10 41.37  11.21 .05*
Triglycerides (mg/dL) 178.03  77.05 195.74  126.66 NS‡
Glucose (mmol/L) 5.7  1.17 6.5  3.33 NS‡
Diabetes 19 (31.1) 14 (37.8) NS†
Uric acid (mmol/L) 0.37  0.11 0.35  0.1 NS*
Creatinine (mg/dL) 1.46  0.72 1.44  0.69 NS‡
Chronic renal failure§ 20 (31.7) 11 (30.6) NS†
Homocysteine (mol/L) 21.53  18.31 23.26  14.76 NS‡
Antihypertensive drugs 2.41  1.12 2.14  1.67 NS‡
Renal artery lumen reduction (%)
50–75 2 (3.1) 14 (38.9)
75–90 36 (56.3) 9 (25)
Subocclusive 26 (40.6) 13 (36.1) NS†
Bilateral RAS 18 (29.5) 9 (26.5) NS†
CAD 26 (43.3) 22 (61.1) NS†
Peripheral arteriopathy (%)
Lower extremities 50.9 72.2 .05†
Carotid artery 61.4 52.8 NS†
Lower extremities and carotid artery 78.9 77.8 NS†
ACE genotype (%)
II 18.5 10 NS†
ID 35.2 33.3
DD 46.3 56.7
Endovascular treatment  revascularization with percutaneous transluminal renal angioplasty, with or without stenting. Stenosis grade reported for main
stenosis in patients with bilateral stenosis.
Numbers in parentheses represent percent.
RAS, Renal artery stenosis; BP, blood pressure; LDL, low-density lipoprotein, HDL, high-density lipoprotein; CAD, coronary artery disease
*Mann-Whitney nonparametric test.
†2 test for qualitative variables.
‡Student t test.
§Createnine concentration  1.5 mg/dL.
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significance of 0.1 were included in the final multivariate
models.
For ACE I/D polymorphism, dummy variables were
created for the various genotypes, with the II genotype as
reference. To detect a possible specific role of the DD
genotype, a model using II and ID as reference was also
used.
RESULTS
Characteristics of study population
Baseline characteristics of the study population, that is,
the ET group (n  63) and the CT group (n  37), are
shown in Table I. The groups were generally well-matched
for most clinical features, but differed in age, diastolic
blood pressure, high-density lipoprotein cholesterol, and
prevalence of lower extremity atherosclerosis. Although a
high frequency of DD genotype was observed in the pop-
ulation as a whole (II 15.8%, ID 35.8%, DD 48.4%),
there was no difference in ACE genotype distribution be-
tween the two groups.
Follow-up
Mortality. Seventeen patients (17%) died during fol-
low-up, 15 as a result of major cardiovascular events, and 2
of neoplastic disease. These latter deaths were regarded as
unrelated to RAS, and were not included in the survival
analysis (Fig 1). The survival curve for 98 subjects, calcu-
lated over a median observation period of 28 months, is
shown in Fig 1, A. Cumulative probability of survival was
93.51% after 1 year and 70.7% after 5 years. Fig 1, B shows
survival curves for patients subdivided according to treat-
ment group: at the end of follow-up, survival probability in
patients who underwent PTRA or PTRA-S was 86.74%,
compared with 67.13% for those in the CT group. Baseline
clinical features, possibly associated with mortality, were
tested with Cox regression analysis. Table II presents the
variables that achieved a level of significance of 0.1 and were
included in the final multivariate regression model. An
independent predictor of survival was endovascular treat-
ment, which was associated with a substantial reduction in
mortality (hazard ratio, 0.31; 95% confidence interval [CI],
0.1-0.96; Table II). Baseline Cr concentration greater than
1.5 mg/dL was associated with lower probability of sur-
vival (P  .05; hazard ratio, 2.87; 95% CI, 1-8.27). Al-
though a lower proportion of survivors had CAD at diag-
nosis (42.5% vs 86.7%; P  .01), the presence of CAD
failed to prove statistically significant when adjusted for the
other variables in the multivariate Cox model (Table II).
Similarly, in the same model age was not a useful predictor
of mortality. ACE DD genotype distribution was not asso-
ciated with mortality (35.7% deceased and 49.4% surviving
patients had the DD genotype; P  NS; Table III).
In the population as a whole, 47 patients (26 in the ET
group and 21 in the CT group) had evidence of CAD.
Endoscopic therapy still afforded an advantage in terms of
survival in this subgroup; mortality was twice as high in the
CT compared with the ET group (38.1% vs 19.2%), al-
though because of the small size of the sample the differ-
ence is not statistically significant (P  .15)
Improvement in blood pressure. Hypertension was
not cured in any our study patients, including those who
underwent revascularization at PTRA or PTRA-S. How-
ever, during follow-up blood pressure improved signifi-
cantly in a larger proportion of patients in the ET group
than in the CT group (57.4% vs 29%; P  .05; Fig 2, A).
Baseline clinical features possibly associated with blood
pressure control are reported in Table II. Only treatment
with PTRA or PTRA-S (odds ratio [OR], 3.21; 95% CI,
1.06-9.7) was associated with a significantly increased
probability of blood pressure improvement in the final
logistic regression model. Other variables tested, including
Fig 1. Adjusted survival in the 98 study patients in the overall population (A) and the two study groups (B). ET,
Endovascular therapy; CT, conservative treatment.
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ACE DD genotype, were not associated with subsequent
blood pressure control.
Renal function. About half of the patients (48.4%) in
the CT group exhibited renal function deterioration during
follow-up, confirming the view that ischemic nephropathy
is a progressive disease (Fig 2, B). In contrast, during the
same period, significant impairment of renal function was
observed in only 17.9% of patients in the ET group. In the
final logistic regression model, outcome was predicted only
by revascularization treatment (OR, 3.65; 95% CI, 1.28-
10.46) and age (OR, 0.91; 95% CI, 0.84-0.99; Table II).
Baseline Cr concentration, diabetes, bilateral stenosis, and
ACE DD genotype were not predictive of further func-
tional worsening.
Arterial recurrent stenosis. Significant recurrent ste-
nosis developed in 11 patients (21.6%) in the ET group.
The rate of recurrent stenosis was higher in patients who
underwent PTRA than in those who underwent PTRA-S
(42.9% vs 18.5%), but the difference was not statistically
significant (P .1) because of the small number of patients.
ACE DD genotype, bilateral RAS, blood pressure control,
and cholesterol levels were not associated with a higher
incidence of recurrent stenosis. Recurrent stenosis was gen-
erally associated with poor probability of improved blood
pressure (22.2% of patients with recurrent stenosis vs 53.1%
of patients without recurrent stenosis; data not shown).
DISCUSSION
We evaluated the clinical course in 100 patients with
atherosclerotic RAS and analyzed factors associated with
subsequent mortality, blood pressure control, decline in
renal function, and arterial recurrent stenosis after a revas-
cularization procedure. Three main results were obtained.
First, the prognosis was poor in patients who did not
undergo PTRA or PTRA-S but received conservative treat-
ment with hypotensive drugs; 10 of 36 patients died, blood
pressure was still inadequately controlled in 71%, and nearly
half had worsened renal function (Figs 1, 2). Second,
endovascular revascularization had a considerable effect on
the course of renovascular disease, substantially reducing its
adverse consequences (Fig 1; Table II). Finally, the DD
genotype, though frequent in these patients, was not con-
firmed as predictive of mortality (Table III). This suggests
that ACE DD may favor a mechanism that leads to devel-
opment of arterial stenosis, but that the later clinical evo-
lution of renovascular disease occurs independent of this
genetic factor.
Mortality rate. Mortality in patients in the CT group
was significantly higher than in the ET group. This result,
however, requires critical interpretation. When planning
the study, we exploited the opportunity offered by the
various treatment strategies in two departments in our
hospital after RAS detection at angiography. The two treat-
ment groups, however, were not similar with regard to
baseline variables. Because this was a retrospective study,
patients included were not randomized for treatment, and
the choice of therapy was based, at least in part, on individ-
ual clinical factors. There is, therefore, an element of bias
inherent in this type of selection. When this limitation is
taken into account, there still appears to be a favorable
effect of ET on mortality from renovascular disease, for
Table II. Regression models for main clinical outcomes




Cox proportional hazard regression
Death due to cardiovascular cause Percutaneous revascularization .05 0.31 0.1–0.96
Coronary artery disease .07 4.32 0.91–20.58
Age .17 1.07 0.98–1.17
Basal serum creatinine  132.6




Blood pressure improvement Percutaneous revascularization .05 3.21 1.06–9.7
Bilateral RAS .06 3.23 0.97–10.83
Diastolic BP .2 1.04 0.98–1.1
Number of antihypertensive drugs .07 1.6 0.95–2.69
Stable or improved renal function Percutaneous revascularization .05 3.65 1.28–10.46
Age .05 0.91 0.84–0.99
Basal serum creatinine  132.6
mol/L ( 1.5 mg/dL)
.15 2.18 0.75–6.38
RAS, Renal artery stenosis; BP, blood pressure; CI, 95% confidence interval; OR, odds ratio.
Table III. ACE I/D polymorphism distribution in
relation to mortality
Mortality (%) ACE I/I ACE I/D ACE D/D
Died 21.4 42.9 35.7
Survived 15.2 35.4 49.4
P not significant (2 test).
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the following reasons. At multivariate logistic regression
analysis, a protective role of ET was still observed after
adjustment for all remaining covariates, including CAD
prevalence; separate comparison of the 47 patients with
renovascular disease, all similarly affected with CAD,
demonstrated that ET was still capable of affording an
advantage in terms of survival; the ET and CT patient
groups were similarly affected by the main traditional risk
factors, and the overall burden of vascular disease was
similar in the two groups (Table I).
In a study of 3987 patients with CAD, presence of RAS
was a strong independent predictor of mortality, and sever-
ity of arterial stenosis had an incremental effect on mortal-
ity.7 Although specific studies are lacking, our preliminary
results suggest that patients with CAD with renovascular
disease could particularly benefit from early renal
revascularization.
The finding that baseline renal impairment is associated
with higher mortality in RAS is in agreement with previous
reports,10,22-24 confirming that preservation of renal func-
tion is one of the main therapeutic goals.
The three controlled randomized trials that compared
revascularization and medical therapy12-14 are an important
reference in this field. However, duration of follow-up in
two of the three trials was no longer than 12 months, with
the result that conclusions about treatment and long-term
RAS mortality could not be drawn. This is an important
issue investigated in our study, and adds fresh material to
the debate fuelled by conflicting results reported by others.
Both neutral and unfavorable long-term clinical effect of
conservative treatment on the natural history of RAS have
been reported.3,6,25
Blood pressure control. The only baseline patient
feature associated with significant predictive power of sub-
sequent blood pressure improvement was the revasculariza-
tion procedure. In the context of the debate regarding the
indication for endovascular therapy, our study provides
evidence of better outcome after restoration of lumen
patency compared with conservative therapy alone. Never-
theless, there is still no consensus as to which is the better
treatment. Two of the most frequently cited studies are
randomized controlled trials that compare conservative and
endovascular treatment. In these studies, the two treat-
ments showed no statistically significant difference in major
outcome.12,13 However, in both cases the revascularization
procedure was PTRA, which is associated with a high rate
of recurrent stenosis, and a substantial proportion of pa-
tients assigned to drug therapy underwent balloon angio-
plasty after a few months, because of inadequate blood
pressure control, thus making any long-term comparison
impossible. These issues have therefore been criticized, and
caution is warranted before any firm conclusion can be
made.26,27 In this context, our study adds evidence in favor
of better long-term outcome in patients who underwent
endovascular therapy compared with those who received
pharmacologic therapy alone. This result reflects the pre-
vailing use of PTRA-S rather than PTRA in our patients, in
agreement with most studies that compared both technical
procedures.11,28 A randomized controlled prospective trial
comparing PTRA-S and medical therapy will probably be
necessary to definitively settle the controversy, but such a
study will be difficult to conduct, because of ethical reasons.
Renal function. In our patients, endovascular therapy
was associated with long-term stabilization or improve-
ment in renal function. Despite similar baseline Cr concen-
tration, long-term decline in renal function was observed in
17.9% of patients in the ET group compared with 48.5% in
the CT group.
This result was observed in a population with normal or
slightly increased Cr concentration (1.46  0.72 mg/dL;
70% of patients with Cr 1.5 mg/dL), whereas in most
published studies greater benefit was observed in patients
with more severe renal impairment.8-9,11,22,29 In patients
with normal renal function, no significant decrease in Cr
concentration has generally been described after endovas-
cular therapy.10,12,13,30 In keeping with these results, only
in a minority of our patients did Cr concentration decrease
after PTRA or PTRA-S (21.4%), whereas in most patients
Fig 2. Clinical outcome in the two treatment groups. A, Blood pressure control. B, Renal function.
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renal function remained unchanged (60.7%). In other
words, endovascular therapy “preserved” renal function
against long-term progressive decline, as observed in the
CT group. Thus our findings suggest that an early inter-
ventional approach may substantially delay progression of
renal dysfunction, thus avoiding overt ischemic nephropa-
thy and ultimately end-stage renal disease.
Recurrent stenosis. Evaluation of recurrent stenosis
rate in patients in the ET group was not the primary
purpose of our study because of the small number of
patients who underwent revascularization, among other
issues. The recurrent stenosis rate (18.5% and 42.9% in
patients who underwent PTRA-S or PTRA, respectively)
was similar to that reported by most authors,9,10,24,31
confirming PTRA-S as the best procedure. Worthy of note,
in our patients recurrent stenosis was not associated with
improvement in blood pressure, thus providing support for
the positive role of renal artery patency in obtaining ade-
quate blood pressure control.
ACE gene deletion polymorphism. Our data do not
confirm the findings of Losito et al18 of an association
between the ACE DD genotype and higher mortality in
patients with renovascular disese, despite similar genotype
frequency and larger sample in our study. The different
results could be related to the proportion of patients who
underwent endovascular therapy in the two studies, but this
cannot be compared because pertinent information is not
provided by Losito and colleagues.
In our patients, the DD genotype was not associated
with a decline in renal function, blood pressure control, or
recurrent stenosis after PTRA or PTRA-S. It is possible that
ACE inhibitors, which were used in a substantial propor-
tion of our patients, might have limited production of
angiotensin II (constitutively increased in patients with the
DD genotype), thus reducing the clinical effect of ACE
gene polymorphism. It is also reasonable to speculate that
high concentration of angiotensin II, associated with the
DD genotype, may initially favor the formation of athero-
sclerotic plaques, but that when hemodynamically signifi-
cant arterial stenosis is established no further angiotensin II
production is possible, regardless of ACE I/D genotype.
ADDITIONAL REMARKS
It is by no means easy to fully explain how revascular-
ization can improve survival in patients with RAS, even
when taking into account the important overall burden of
vascular disease presented by most, if not all, of these
patients. Preservation of renal function and better blood
pressure control may be important mechanisms, but the
extent of the changes does not appear sufficient to account
for all the benefits observed in terms of survival. Some
recently published contributions could be potentially im-
portant for understanding this problem. These findings
suggest that in patients with renovascular hypertension
excessive oxidative stress may be involved in systemic im-
paired endothelium-dependent vasodilation.32,33 More-
over, successful renal revascularization and consequent
downregulation of the renin-angiotensin system decreases
oxidative stress and improves systemic endothelium-depen-
dent vasodilation. Therefore PTRA or PTRA-S may in-
crease the general bioavailability of nitric oxide by inhibit-
ing production of angiotensin and amplifying the “renal
effect” at the systemic level. Of interesting, similar data
have been obtained in atherosclerotic and fibrodysplastic
artery stenosis, suggesting that vascular occlusion and re-
nin-angiotensin system activation may prevail over the clas-
sic atherogenic risk factors.
CONCLUSIONS
Renovascular disease is a severe progressive condition
associated with poor prognosis if untreated or detected late.
The therapeutic measure most suited to delaying this unfa-
vorable course is early endovascular revascularization, pref-
erably with PTRA-S.
We thank Patrizia Guarini, PhD, for assistance with
laboratory testing, and Chiara Pavan, MD, for collaborat-
ing on data collection.
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